These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 22574612)

  • 1. Predictors of the short-term effect of isoleucine-proline-proline/valine-proline-proline lactotripeptides from casein on office and ambulatory blood pressure in subjects with pharmacologically untreated high-normal blood pressure or first-degree hypertension.
    Cicero AF; Rosticci M; Ferroni A; Bacchelli S; Veronesi M; Strocchi E; Borghi C
    Clin Exp Hypertens; 2012; 34(8):601-5. PubMed ID: 22574612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lactotripeptides effect on office and 24-h ambulatory blood pressure, blood pressure stress response, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first-degree hypertension: a randomized double-blind clinical trial.
    Cicero AF; Rosticci M; Gerocarni B; Bacchelli S; Veronesi M; Strocchi E; Borghi C
    Hypertens Res; 2011 Sep; 34(9):1035-40. PubMed ID: 21753776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Lactotripeptides (Isoleucine-Proline-Proline/Valine-Proline-Proline) on Blood Pressure and Arterial Stiffness Changes in Subjects with Suboptimal Blood Pressure Control and Metabolic Syndrome: A Double-Blind, Randomized, Crossover Clinical Trial.
    Cicero AF; Colletti A; Rosticci M; Cagnati M; Urso R; Giovannini M; Borghi C; D'Addato S
    Metab Syndr Relat Disord; 2016 Apr; 14(3):161-6. PubMed ID: 26683986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of long-term intake of lactotripeptides on cardiovascular risk factors in hypertensive subjects.
    Jauhiainen T; Niittynen L; Orešič M; Järvenpää S; Hiltunen TP; Rönnback M; Vapaatalo H; Korpela R
    Eur J Clin Nutr; 2012 Jul; 66(7):843-9. PubMed ID: 22617279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lactotripeptides show no effect on human blood pressure: results from a double-blind randomized controlled trial.
    Engberink MF; Schouten EG; Kok FJ; van Mierlo LA; Brouwer IA; Geleijnse JM
    Hypertension; 2008 Feb; 51(2):399-405. PubMed ID: 18086944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic effects of lactotripeptides from casein hydrolysate in Mediterranean normotensive subjects and patients with high-normal blood pressure: a randomized, double-blind, crossover clinical trial.
    Cicero AF; Rosticci M; Veronesi M; Bacchelli S; Strocchi E; Melegari C; Grandi E; Borghi C
    J Med Food; 2010 Dec; 13(6):1363-8. PubMed ID: 21091250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of the Lactotripeptides Isoleucine-Proline-Proline and Valine-Proline-Proline on Systolic Blood Pressure in Japanese Subjects: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Chanson-Rolle A; Aubin F; Braesco V; Hamasaki T; Kitakaze M
    PLoS One; 2015; 10(11):e0142235. PubMed ID: 26536628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The blood pressure lowering effect of lactotripeptides and salt intake in 24-h ambulatory blood pressure measurements.
    Yamasue K; Morikawa N; Mizushima S; Tochikubo O
    Clin Exp Hypertens; 2010 Jul; 32(4):214-20. PubMed ID: 20608891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dependent lowering of blood pressure by dairy peptides in mildly hypertensive subjects.
    de Leeuw PW; van der Zander K; Kroon AA; Rennenberg RM; Koning MM
    Blood Press; 2009; 18(1-2):44-50. PubMed ID: 19247842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study.
    Mallion JM; Chamontin B; Asmar R; De Leeuw PW; O'Brien E; Duprez D; O'Rourke MF; Rahn KH; Romero R; Battegay E; Hitzenberger G; Safar ME;
    Am J Hypertens; 2004 Mar; 17(3):245-51. PubMed ID: 15001199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of low felodipine dose monotherapy in mild-to-moderate hypertension: a comparison between office and ambulatory blood pressure monitoring.
    Podjarny E; Korzets Z; Bernheim J
    J Hum Hypertens; 1996 Sep; 10 Suppl 3():S153-6. PubMed ID: 8872849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
    Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ile-Pro-Pro and Val-Pro-Pro tripeptide-containing milk product has acute blood pressure lowering effects in mildly hypertensive subjects.
    Turpeinen AM; Ehlers PI; Kivimäki AS; Järvenpää S; Filler I; Wiegert E; Jähnchen E; Vapaatalo H; Korpela R; Wagner F
    Clin Exp Hypertens; 2011; 33(6):388-96. PubMed ID: 21649532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Casein hydrolysate containing the antihypertensive tripeptides Val-Pro-Pro and Ile-Pro-Pro improves vascular endothelial function independent of blood pressure-lowering effects: contribution of the inhibitory action of angiotensin-converting enzyme.
    Hirota T; Ohki K; Kawagishi R; Kajimoto Y; Mizuno S; Nakamura Y; Kitakaze M
    Hypertens Res; 2007 Jun; 30(6):489-96. PubMed ID: 17664851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
    Knudsen ST; Andersen NH; Poulsen SH; Eiskjaer H; Hansen KW; Helleberg K; Poulsen PL; Mogensen CE
    Am J Hypertens; 2008 Feb; 21(2):172-6. PubMed ID: 18188164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do the lactotripeptides isoleucine-proline-proline and valine-proline-proline reduce systolic blood pressure in European subjects? A meta-analysis of randomized controlled trials.
    Cicero AF; Aubin F; Azais-Braesco V; Borghi C
    Am J Hypertens; 2013 Mar; 26(3):442-9. PubMed ID: 23382495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Casein hydrolysate containing Val-Pro-Pro and Ile-Pro-Pro improves central blood pressure and arterial stiffness in hypertensive subjects: a randomized, double-blind, placebo-controlled trial.
    Nakamura T; Mizutani J; Ohki K; Yamada K; Yamamoto N; Takeshi M; Takazawa K
    Atherosclerosis; 2011 Nov; 219(1):298-303. PubMed ID: 21723554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients.
    de la Sierra A; Gil-Extremera B; Calvo C; Campo C; García-Puig J; Márquez E; Oliván J; Roca Cusachs A; Sanz de Castro S; Pontes C; Delgadillo J
    J Hum Hypertens; 2004 Mar; 18(3):215-22. PubMed ID: 14973517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring.
    Karotsis AK; Symeonidis A; Mastorantonakis SE; Stergiou GS;
    Clin Exp Hypertens; 2006 Oct; 28(7):655-62. PubMed ID: 17060064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.